Effects of Anticoagulant Therapy and Frailty in the Elderly Patients with Atrial Fibrillation [Letter].
作者信息
Zhang Huaguo, Wang Song, Jiang Xiaolian
机构信息
Department of Nursing, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China.
West China School of Nursing/West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
出版信息
Clin Interv Aging. 2024 Apr 12;19:611-612. doi: 10.2147/CIA.S468526. eCollection 2024.
Abstract
摘要
相似文献
1
Effects of Anticoagulant Therapy and Frailty in the Elderly Patients with Atrial Fibrillation [Letter].抗凝治疗与衰弱对老年房颤患者的影响[信函]
Clin Interv Aging. 2024 Apr 12;19:611-612. doi: 10.2147/CIA.S468526. eCollection 2024.
2
Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation.衰弱患者心房颤动抗凝治疗的有效性和安全性。
Stroke. 2022 Jun;53(6):1873-1882. doi: 10.1161/STROKEAHA.121.036757. Epub 2022 Feb 3.
3
Geriatric Elements and Oral Anticoagulant Prescribing in Older Atrial Fibrillation Patients: SAGE-AF.老年因素与老年心房颤动患者口服抗凝药物的应用：SAGE-AF。
J Am Geriatr Soc. 2020 Jan;68(1):147-154. doi: 10.1111/jgs.16178. Epub 2019 Oct 1.
4
Influence of frailty on anticoagulant prescription and clinical outcomes after 1-year follow-up in hospitalised older patients with atrial fibrillation.衰弱对住院老年房颤患者抗凝治疗方案选择及 1 年临床预后的影响。
Intern Emerg Med. 2019 Jan;14(1):59-69. doi: 10.1007/s11739-018-1938-3. Epub 2018 Sep 6.
5
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.非瓣膜性心房颤动虚弱患者中阿哌沙班、达比加群和利伐沙班与华法林的有效性和安全性。
J Am Heart Assoc. 2018 Apr 13;7(8):e008643. doi: 10.1161/JAHA.118.008643.
6
Which anticoagulant is safest for frail elderly patients with nonvalvular A-fib?哪种抗凝剂对非瓣膜性房颤的体弱老年患者最安全？
J Fam Pract. 2022 Nov;71(9):407-409. doi: 10.12788/jfp.0509.
7
Anticoagulant Therapy for Frail Patients with Atrial Fibrillation.衰弱患者心房颤动的抗凝治疗。
Intern Med. 2021;60(4):495-506. doi: 10.2169/internalmedicine.6077-20. Epub 2021 Feb 15.
8
Comment on: Differential effect of anticoagulation according to cognitive function and frailty in older patients with atrial fibrillation.关于《老年房颤患者认知功能和衰弱对抗凝治疗的不同影响》的评论
J Am Geriatr Soc. 2023 Aug;71(8):2669-2670. doi: 10.1111/jgs.18367. Epub 2023 Apr 3.
9
Assessment of the bleeding risk of anticoagulant treatment in non-severe frail octogenarians with atrial fibrillation.评估非重度虚弱 80 岁以上老年房颤患者抗凝治疗的出血风险。
J Cardiol. 2019 Jan;73(1):7-13. doi: 10.1016/j.jjcc.2018.05.012. Epub 2018 Jun 10.
10
Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial.老年体弱房颤患者从维生素K拮抗剂转换为非维生素K拮抗剂口服抗凝剂的安全性：FRAIL-AF随机对照试验的原理与设计
BMJ Open. 2019 Dec 29;9(12):e032488. doi: 10.1136/bmjopen-2019-032488.
本文引用的文献
1
Effects of Anticoagulant Therapy and Frailty in the Elderly Patients with Atrial Fibrillation.抗凝治疗与衰弱对老年房颤患者的影响
Clin Interv Aging. 2024 Feb 14;19:247-254. doi: 10.2147/CIA.S453527. eCollection 2024.
2
Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis.直接口服抗凝剂（DOACs）与华法林在房颤合并虚弱患者中的有效性和安全性：一项系统评价和荟萃分析
Front Cardiovasc Med. 2022 Jun 24;9:907197. doi: 10.3389/fcvm.2022.907197. eCollection 2022.
3
Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation.衰弱患者心房颤动抗凝治疗的有效性和安全性。
Stroke. 2022 Jun;53(6):1873-1882. doi: 10.1161/STROKEAHA.121.036757. Epub 2022 Feb 3.
Zotero 插件